monash ivf underlying profits fell in fy25

Monash IVF (ASX:MVF) reported revenue from ordinary activities up 6.7% to $271.917 million. However, underlying net profit after tax attributable to members and minority interest fell 8.1% to $27.419 million. Earnings before interest and tax (EBIT) decreased to $43.412 million. The prior corresponding period showed a profit of $25.008 million. The final dividend for the year ended 30 June 2024 per ordinary share paid on 11 October 2024 was 2.5 cents. There is no direct quote available, therefore a third paragraph with additional relevant contextual information that supports or elaborates on the key facts already presented will be included. The domestic IVF business saw a 5.0% decrease in stimulated cycles. However, clinical pregnancy rates per embryo transferred (women aged younger than 43 years) increased a further 0.2% to 40.3% since CY2020. The FY26 Underlying Group NPAT is expected to be between $20M and $23M compared to $27.4M in FY25, reflecting lower domestic IVF new patient registrations and deferral of IVF patient price increases.

Earnings before interest and tax (EBIT) decreased to $43.412 million. The prior corresponding period showed a profit of $25.008 million. The final dividend for the year ended 30 June 2024 per ordinary share paid on 11 October 2024 was 2.5 cents.

There is no direct quote available, therefore a third paragraph with additional relevant contextual information that supports or elaborates on the key facts already presented will be included.

The domestic IVF business saw a 5.0% decrease in stimulated cycles. However, clinical pregnancy rates per embryo transferred (women aged younger than 43 years) increased a further 0.2% to 40.3% since CY2020.

The FY26 Underlying Group NPAT is expected to be between $20M and $23M compared to $27.4M in FY25, reflecting lower domestic IVF new patient registrations and deferral of IVF patient price increases.